Influenza and Other Respiratory Viruses最新文献

{"title":"Respiratory Syncytial Virus Hospitalizations Among Adults in Thailand: A Nationwide Retrospective Observational Study (RSV-HAT).","authors":"Kanrutai Jarottammarat, Kanokkarn Pinyopornpanish, Chadakan Yan, Bussakorn Mahakkanukrauh, Otavio Cintra, Adriana Guzman-Holst, Phichayut Phinyo, Wipa Reechaipichitkul","doi":"10.1111/irv.70263","DOIUrl":"https://doi.org/10.1111/irv.70263","url":null,"abstract":"<p><strong>Background: </strong>Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI) in adults, especially older individuals, yet data on burden in Thailand are limited. This study aimed to describe clinical characteristics and mortality risk factors of RSV-related hospitalizations in Thai adults.</p><p><strong>Methods: </strong>We conducted a retrospective analysis using Thailand's national hospital database, including adults aged ≥ 18 years hospitalized with RSV-associated ARIs between June 2016 and September 2024, identified using ICD-10 codes J12.1, J20.5, J21.0, and B97.4. Demographics, case fatality ratio, and healthcare resource utilization were assessed. Multivariable logistic regression identified predictors of in-hospital mortality, and Kaplan-Meier analysis estimated 60-day overall survival by age and comorbidity status.</p><p><strong>Results: </strong>Among 1595 RSV-related hospitalizations, the mean age was 66.5 years; 72.0% were aged ≥60 years and 78.4% had ≥ 1 comorbidity, most commonly hypertension, diabetes, chronic respiratory disease, and chronic heart disease. The median length of stay (LOS) was 7 days, 17.3% required oxygen therapy, and 8.2% received invasive mechanical ventilation (IMV). The in-hospital mortality was 9.53%. Mortality was independently associated with age ≥ 75 years (mOR 1.83, p = 0.019), LOS ≥ 7 days (1.95, p = 0.001), IMV (2.94, p < 0.001), pneumonia (4.10, p < 0.001), and acute myocardial infarction (3.05, p = 0.005). The 60-day survival rate was 88.2%, declining to 84.0% in patients aged ≥ 75 years (p < 0.001) and 87.1% in those with comorbidities versus 92.2% in those without (p = 0.013).</p><p><strong>Conclusions: </strong>RSV causes substantial morbidity and mortality in Thai adults, especially those aged ≥ 75 years and with chronic comorbidities, underscoring the need for strengthened RSV surveillance and prevention strategies.</p><p><strong>Trial registration: </strong>Thai Clinical Trials Registry: TCTR20250929005.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 5","pages":"e70263"},"PeriodicalIF":4.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence and Rapid Spread of a New Reassortant High Pathogenicity H5N1 Clade 2.3.4.4b Avian Influenza Virus in Nigeria.","authors":"Clement Meseko, Bianca Zecchin, Emilie Wolali Go-Maro, Marta Dianati, Nicodemus Mkpuma, Bitrus Inuwa, Judith Bakam, Kayode Olawuyi, Dorcas Gado, Edoardo Giussani, Alice Fusaro, Alessio Bortolami, Elisa Palumbo, Calogero Terregino, Isabella Monne","doi":"10.1111/irv.70260","DOIUrl":"https://doi.org/10.1111/irv.70260","url":null,"abstract":"<p><p>Over the past two decades, West Africa has experienced recurrent incursions of Goose/Guangdong-lineage highly pathogenic avian influenza (HPAI) A(H5N1), with Nigeria as a hotspot for repeated introductions and sustained circulation. Since 2021, European-origin clade 2.3.4.4b H5Nx genotypes, particularly EA-2020-C, have predominated in regional poultry. Here, we report the emergence and rapid spread in Nigeria, and West Africa, of a new clade 2.3.4.4b H5N1 genotype, designated EA-2024-DV, marking a major shift in the circulating virus population. These findings underscore the region's ongoing vulnerability to novel introductions and highlight the need for sustained surveillance across migratory bird routes and poultry production networks.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 5","pages":"e70260"},"PeriodicalIF":4.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Influenza and Cost-Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India.","authors":"Anand Krishnan, Aslesh Ottapura Prabhakaran, Kusum Shekhawat, Ismael R Ortega-Sanchez, Rakesh Kumar, Ritvik Amarchand, Prabu Rajkumar, Suman Kanungo, Sumit Dutt Bhardwaj, Giridara Gopal, Girish Kumar Chethrapilly Purushothaman, Varsha Potdar, Alok Kumar Chakrabarti, Radhika Gharpure, Avinash Choudekar, Kathryn E Lafond, Lalit Dar, Siddhartha Saha, Kathrine R Tan, Eduardo Azziz-Baumgartner","doi":"10.1111/irv.70264","DOIUrl":"https://doi.org/10.1111/irv.70264","url":null,"abstract":"<p><strong>Background: </strong>In India, no publicly funded seasonal influenza immunization is ongoing, partly because cost-effectiveness is yet to be established. We estimate the cost-effectiveness and budgetary impact of introducing seasonal influenza vaccination among adults aged ≥ 60 years in India, a known high-risk group.</p><p><strong>Methods: </strong>Estimates of disease burden including disability adjusted life years (DALYs) were generated from 3-year community cohorts and hospital-based study set up at four sites to estimate incidence of symptomatic acute respiratory infections (ARI), health care utilization, costs and outcomes and applied to India's 2021 estimated population. We used a decision analysis model from an abridged societal perspective for implementation of an inactivated trivalent influenza vaccination programme for older adults (aged ≥ 60 years) using either facility-based or outreach-based approaches. We estimated incremental cost-effectiveness ratio (ICER) per DALY averted and used India's per capita gross domestic product of US$ 2238 for 2021 as the cost-effectiveness threshold. We performed deterministic and probabilistic sensitivity analyses. We also estimated ICER for immunizing all those above 65 years or with comorbidities. Using financial cost of the vaccination programme and the direct medical cost of disease averted we estimated its budgetary impact.</p><p><strong>Results: </strong>In 2021, older adults in India had 5.3 (95% CI: 3.6-7.7) million influenza-ARIs resulting in 36,149 (95% CI: 30,076-43,268) hospitalizations and 84,613 (95% CI: 39,895-155,454) deaths. It amounted to a total of 974,019 DALYs and US$ 66.6 million. As compared with no vaccination, facility-based and outreach-based influenza vaccination had an ICER of US$1979 and US$1851, respectively, below the cost-effectiveness threshold. In all sensitivity and scenario analyses, ICER estimates were below the threshold and vaccinating those above 60 years with specified comorbidities using a passive approach was found to be most cost-effective with least budgetary impact.</p><p><strong>Conclusion: </strong>Annually vaccinating older adults against influenza was found to be cost-effective in the majority of scenarios considered in the study. Given the budgetary implication, it might be prudent to focus on those with co-morbidities.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 5","pages":"e70264"},"PeriodicalIF":4.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13132663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imported SARS-CoV-2 Infections at N'djili International Airport in Kinshasa, Democratic Republic of Congo: An Epidemiological and Genomic Analysis.","authors":"Agar Mpwo Matalatala, Bive Bive Zono, Trésor Mampuela Kabeya, Héritier Kabenge Motemankele, Doudou Malekita Yobi, Elisabeth Simbu Pukuta, Placide Kingebeni Mbala, Georges Lelo Mvumbi","doi":"10.1111/irv.70259","DOIUrl":"https://doi.org/10.1111/irv.70259","url":null,"abstract":"<p><strong>Background: </strong>During the COVID-19 pandemic, international border restrictions, along with traveler screening and quarantine, were implemented to limit virus spread. This study analyzes the epidemiological and genomic profiles of SARS-CoV-2 infections imported into Kinshasa (DRC) during the restrictions period in 2021.</p><p><strong>Methods: </strong>As part of the national response to the pandemic, self-reported demographic and clinical data were collected from travelers entering the DRC via N'djili-Kinshasa International Airport. SARS-CoV-2 infection was diagnosed using RT-PCR, and positive samples were subjected to whole genome sequencing (WGS) to determine variant types and viral lineages. The impact of the virus's genomic profile on the clinical presentation of travelers and on the COVID-19 epidemiology in the DRC was then assessed.</p><p><strong>Results: </strong>Of 102,810 included travelers, 1037 (1.0%) tested positive for SARS-CoV-2 and reported significantly more nausea, diarrhea, and weight loss than uninfected travelers (p < 0.001). SARS-Cov-2-infected travelers were predominantly under 43 years old (p < 0.001) and primarily from France (24.8%) and Belgium (19.5%). Of the 105 WGS analyzed, 86 (81.9%) were variants of concern (VOCs), 14 (13.3%) were variants under monitoring (VUM), and the main genomic lineages identified were Delta-B.1.617.2 (24.8%), Alpha-B.1.1.7 (10.5%), Delta-AY.122 (7.6%), and B.1.620 (5.7%). The Delta-VOC was the most prevalent among positive travelers (61/86) and appeared to cause more symptomatic infections than non-Delta variants, although one-third of positive travelers reported no symptoms.</p><p><strong>Conclusions: </strong>SARS-CoV-2 importation into Kinshasa (DRC) mirrored global variant circulation patterns at the study's time. This genomic landscape was consistent with in-country clinical observations, emphasizing the importance of robust border surveillance and adaptive public health strategies during pandemics.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 5","pages":"e70259"},"PeriodicalIF":4.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13142099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Influenza Vaccines in Italy in the 2024/2025 Season: A Nationwide, Test-Negative Design Study Based on Surveillance Records.","authors":"Daniel Cifo, Alberto Mateo-Urdiales, Simona Puzelli, Marzia Facchini, Sara Piacentini, Emanuela Giombini, Benedetta Bellini, Massimo Fabiani, Patrizio Pezzotti, Paola Stefanelli, Anna Teresa Palamara, Antonino Bella","doi":"10.1111/irv.70252","DOIUrl":"10.1111/irv.70252","url":null,"abstract":"<p><p>The 2024/2025 influenza season in Italy was characterised by cocirculation of influenza A and B viruses. Monitoring influenza vaccine effectiveness (IVE) remains essential to guide public health policy due to antigenic shifts and varying strain circulation. In this study, we aimed to estimate IVE in primary care and hospital settings during the 2024/2025 season in Italy. A nationwide test-negative control design was used. Data were collected from the RespiVirNet surveillance system, encompassing both primary care and hospital settings. A total of 8842 participants were included in the primary care analysis and 2492 in the hospital analysis. Adjusted vaccine effectiveness (aVE) against any influenza virus was 69.0% (95% CI: 60.4%-75.9%) in primary care and 62.3% (95% CI: 45.9%-74.2%) in hospital settings. Effectiveness was highest among individuals under 18 years and decreased with age. Influenza B showed the highest aVE (83.6% in primary care; 95.0% in hospital settings), particularly among younger individuals. aVE for influenza A subtypes was lower, with A H1N1pdm09 (54.0% in primary care; 63.8% in hospital) and A H3N2 (60.1% in primary care; 45.5% in hospital) showing moderate effectiveness. The results suggest that influenza vaccines were effective in preventing medically attended influenza disease, both in primary care and hospital settings. These findings provide valuable insights for public health planning and vaccine policy in Italy.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 5","pages":"e70252"},"PeriodicalIF":4.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13130019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meeting Report: Fourth Correlates of Protection for Next Generation Influenza Vaccines","authors":"Alina Tscherne,&nbsp;Rebecca Jane Cox,&nbsp;Florian Krammer,&nbsp;Anders Bonnevie","doi":"10.1111/irv.70258","DOIUrl":"10.1111/irv.70258","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This report summarizes the discussions and conclusions from the fourth “Correlates of Protection for Next Generation Influenza Vaccines” meeting, which took place in Vienna, Austria, from October 15, 2025, to October 17, 2025.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Discussions on influenza virus correlates of protection built on prior meetings, with particular emphasis on challenges introduced by novel vaccine platforms and evolving regulatory expectations. Although established immune markers such as hemagglutination inhibiting (HI) antibodies remain central to influenza vaccine evaluation, this year's discussions highlighted the continued uncertainty and challenges around their generalizability across platforms, populations, and age groups. Regulatory perspectives emphasized the need for strong biological and clinical justification linking immune markers to protection. Overall, the meeting highlighted the importance of continued collaboration among academia, industry, and regulatory agencies to advance the identification and validation of correlates of protection, in alignment with priorities outlined in the 2025 influenza research and development road map for influenza vaccines.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 4","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating COVID-19 Transmission in a Series of Cases and Contacts in Three Municipalities of Colombia: Insights From the WHO First Few X Protocol, August 2020–January 2021","authors":"Damaris Heredia,&nbsp;May Bibiana Osorio,&nbsp;Carolina Figueroa,&nbsp;Susanne Ardila,&nbsp;Dayner Vacca,&nbsp;Magdalena Santos,&nbsp;Daniel Velandia,&nbsp;Marcela Mercado,&nbsp;Maritza González,&nbsp;Franklyn Prieto,&nbsp;Ingrid Garcia,&nbsp;Ángel Rodriguez","doi":"10.1111/irv.70132","DOIUrl":"10.1111/irv.70132","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>As part of the framework of preparedness and response to influenza viruses with pandemic potential, the World Health Organization (WHO) has developed a protocol for the characterization of a series of first cases and contacts of an agent with pandemic potential (FFX). At the end of 2019, PAHO/WHO invited Colombia to be among the pilot countries for implementing this protocol. It was conducted by the National Institute of Health of Colombia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The WHO generic protocol was reviewed and adapted to Colombia. In its implementation, a series of 99 cases of COVID-19 and 360 total contacts (159 positive contacts) were evaluated between August 2020 and January 2021 in three municipalities of Colombia. Surveys were conducted, along with RT-PCR and antibody titer tests. Sociodemographic, clinical, and virological transmission conditions were analyzed to calculate the main epidemiological indicators of viral transmission using measures of central tendency and absolute and relative frequencies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 258 cases were confirmed to be positive for COVID-19 for a secondary attack rate of 43%. The most common symptoms were cough, fever, headache, and odynophagia. The percentage of symptomatic contacts, clinical attack rate, incubation period, and serial interval were 34%, 16.2%, 4.6 days, and 4.7 days, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The significant rate of infection and incubation periods among contacts was similar to those reported worldwide. The implementation of the WHO FFX protocol in a novel context allowed the country to test its capacity to implement global studies to determine early public health interventions. The study faced limitations due to the selection bias towards severe cases and challenges in case recruitment and contact tracing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 4","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13058238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence About the Paper \"Effectiveness of High-Dose Influenza Vaccine Against Hospitalisations in Older Adults (FLUNITY-HD): An Individual Level Pooled Analysis\" by Niklas Dyrby Johansen et al., https://doi.org/10.1016/S0140-6736(25)01742-8.","authors":"Miloš Jeseňák, David Řezáč, Laura Colombo","doi":"10.1111/irv.70255","DOIUrl":"10.1111/irv.70255","url":null,"abstract":"","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 4","pages":"e70255"},"PeriodicalIF":4.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13087430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postinfection Pig and Ferret Antisera Show Similar Antigenic Profiles for Human Influenza A(H1N1pdm09) Viruses.","authors":"Ruth Harvey, Tiphaine Cayol, Basudev Paudyal, Alice Lilley, Christine Carr, Catherine Hatton, Emily Briggs, Rodney S Daniels, Samuel Richardson, Thomas P Peacock, Nicola Lewis, Ian Brown, John W McCauley, Elma Tchilian","doi":"10.1111/irv.70261","DOIUrl":"https://doi.org/10.1111/irv.70261","url":null,"abstract":"<p><strong>Background: </strong>Monitoring antigenic drift in human influenza A viruses is essential for vaccine strain selection and ensuring protection against circulating strains. Antigenic drift is traditionally assessed using ferret antisera, which provide monospecific responses and human vaccinee sera, which reflect exposure to multiple antigens. In this study, we evaluated the pig as an alternative source of antisera to study antigenic drift compared with immune responses in ferrets and humans. We included seasonal influenza A(H1N1pdm09) human viruses that had shown different antigenic characteristics when using ferret or human antisera.</p><p><strong>Methods: </strong>Pairs of pigs were inoculated with six human A(H1N1)pdm09 viruses circulating between 2019 and 2023, a period of marked antigenic drift. Pig and ferret antisera raised against these six reference viruses were analysed by haemagglutination inhibition (HI) and virus neutralisation (VN), and homologous and heterologous titre differences were used to assess antigenic reactivity profiles among the viruses between species.</p><p><strong>Results: </strong>Pigs were successfully infected with all strains, shedding virus and producing antibody responses, confirming their susceptibility to human influenza A viruses. Antigenic reactivity of pig antisera was qualitatively comparable to ferret antisera in both HI and VN assays, although maximum homologous antibody titres were significantly higher in ferrets (on average 16-fold for HI and from around 12- to 210-fold for VN). The antisera raised against viruses in circulation in 2019 and before, exemplified by A/Guangdong-Maonan/SWL1536/2019, clade 5a.1, were clearly differentiated by both ferret and pig antisera from those in clade 5a.2 and its derivatives that became predominant.</p><p><strong>Conclusions: </strong>Ferrets and pigs showed comparable responses and both distinguished clade 5a.1 from clade 5a.2. However, neither model recognised antigenically drifted variants from 2019 to 2022, including subclades 5a.2-C, 5a.2a-C.1/C.1.9 and 5a.2a.1-C.1.1/D, which were distinguishable using human postvaccination antisera.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 4","pages":"e70261"},"PeriodicalIF":4.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Qualification of a Pseudotyped Virus-Based Microneutralisation Assay for Influenza D Virus.","authors":"Maria Giovanna Marotta, Tobias Mapulanga, Meshach Maina, Janet Daly, Michele Camero, Pauline Mvan Diemen, Helen E Everett, Emanuele Montomoli, Kelly da Costa, Nigel Temperton, Claudia Maria Trombetta","doi":"10.1111/irv.70245","DOIUrl":"10.1111/irv.70245","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological surveillance of influenza D virus (IDV) has gained increased priority following recent serological findings indicating its potential zoonosis in humans. In this context, it is crucial to develop strong, reproducible, reliable and scalable immunological assays that can be quickly implemented in the surveillance of new emerging threats. Serology is a powerful tool for immune monitoring prior to infection and conducting epidemiological surveillance. However, the traditional microneutralisation (MN) assay requires wild-type viruses, considerably limiting its accessibility for some laboratories. Pseudotyped viruses (PVs) allow for expanded usage since they are safer and more flexible for adaptation to specific strains and enable application in laboratories without implementation in high biosecurity containment.</p><p><strong>Methods: </strong>In this study, we conducted the qualification of a PV-based MN (pMN) assay with IDV-PVs that express the HEF glycoprotein of the D/Swine/Italy/199724-3/2015 strain. The assay functionality was examined using 14 bovine serum samples, assessing key analytical parameters including accuracy, specificity, precision, linearity and robustness.</p><p><strong>Results: </strong>The findings demonstrate the IDV pMN assay to be an effective method for the detection of neutralising antibodies.</p><p><strong>Conclusions: </strong>Therefore, the assay can be a valuable tool to facilitate large-scale surveillance and provide data to inform immunisation strategy development.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"20 4","pages":"e70245"},"PeriodicalIF":4.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13077565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}